Literature DB >> 10385554

The significance of adnexal involvement in endometrial carcinoma.

P P Connell1, J Rotmensch, S Waggoner, A J Mundt.   

Abstract

OBJECTIVE: To evaluate the prognostic significance of and predictive factors for adnexal involvement (AI) in patients with endometrial carcinoma.
METHODS: We retrospectively reviewed the pathological features and outcomes of endometrial carcinoma patients. The prognostic significance of AI was examined by univariate and multivariate analyses. Median follow-up was 30.7 months.
RESULTS: Of the 382 cases reviewed, 40 (10.5%) had AI. Patients with AI had a worse 5-year disease-free (DFS) survival (73.1 vs 37.1%, P < 0.0001) than patients without AI. However, patients with AI had multiple adverse features, including high grade disease, lymphovascular invasion, and additional sites of extrauterine disease. After controlling for these factors on multivariate analysis, AI lost its prognostic significance (P = 0.56). The 12 AI patients without other extrauterine disease had a favorable outcome (5-year DFS of 70.9%). Factors predictive of AI on logistic regression were metastatic disease, positive peritoneal washings, cervical involvement, and unfavorable histology.
CONCLUSION: Endometrial carcinoma patients with AI have relatively poor prognoses. However, AI per se has little, if any, independent prognostic significance. The poor outcomes seen in these patients appear to result from the preponderance of other adverse pathologic factors. Copyright 1999 Academic Press.

Entities:  

Mesh:

Year:  1999        PMID: 10385554     DOI: 10.1006/gyno.1999.5415

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

Authors:  Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2021-02       Impact factor: 4.064

2.  Comparison of FIGO 1988 and 2009 staging systems for endometrial carcinoma.

Authors:  Melis Gultekin; Ferah Yildiz; Gokhan Ozyigit; Havva Beyaz; Mutlu Hayran; Faruk Kose; Kunter Yuce; Ali Ayhan
Journal:  Med Oncol       Date:  2012-03-14       Impact factor: 3.064

Review 3.  Endometrial cancer: the management of high-risk disease.

Authors:  Gunnar Kristensen; Claes Tropé
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

4.  Premenopausal early-stage endometrial carcinoma patients with low CA-125 levels and low tumor grade may undergo ovary-saving surgery.

Authors:  Seung-Chul Yoo; Jong-Hyuck Yoon; Woo Young Kim; Suk-Joon Chang; Hee-Jae Joo; Ki-Hong Chang; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2009-09-30       Impact factor: 4.401

5.  Outcome of Endometrial Cancer Stage IIIA with Adnexa or Serosal Involvement Only.

Authors:  Jan J Jobsen; Lambert Naudin Ten Cate; Marnix L M Lybeert; Astrid Scholten; Elzbieta M van der Steen-Banasik; Job van der Palen; Marika C Stenfert Kroese; Annerie Slot; Eltjo M J Schutter; Sabine Siesling
Journal:  Obstet Gynecol Int       Date:  2011-05-04

6.  Adjuvant Treatment after Surgery in Stage IIIA Endometrial Adenocarcinoma.

Authors:  Mee Sun Yoon; Seung Jae Huh; Hak Jae Kim; Young Seok Kim; Yong Bae Kim; Joo-Young Kim; Jong-Hoon Lee; Hun Jung Kim; Jihye Cha; Jin Hee Kim; Juree Kim; Won Sup Yoon; Jin Hwa Choi; Mison Chun; Youngmin Choi; Kang Kyoo Lee; Myungsoo Kim; Jae-Uk Jeong; Sei Kyung Chang; Won Park
Journal:  Cancer Res Treat       Date:  2015-10-29       Impact factor: 4.679

7.  Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression.

Authors:  Alba Mota; Sara S Oltra; Pier Selenica; Cristian P Moiola; Carlos Casas-Arozamena; Carlos López-Gil; Eva Diaz; Sonia Gatius; María Ruiz-Miro; Ana Calvo; Alejandro Rojo-Sebastián; Pablo Hurtado; Roberto Piñeiro; Eva Colas; Antonio Gil-Moreno; Jorge S Reis-Filho; Laura Muinelo-Romay; Miguel Abal; Xavier Matias-Guiu; Britta Weigelt; Gema Moreno-Bueno
Journal:  Oncogene       Date:  2022-02-10       Impact factor: 9.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.